Valeant Falls on its Sword, Carl June’s Curious Omission, & Witty’s Swan Song

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Allen’s $125M Bet on Immunology, Gilead’s New CEO, & Insulin Price-Gouging Scrutiny
CRISPR Babies, Ireland’s Bold Genomics Move, and a Flurry of FDA Approvals
Moderna’s Mega-IPO Plan, AbbVie Nails HCV, & SVB Takes Out Leerink
Sage Postpartum Depression Drug Passes Scrutiny, Blavatnik’s $200M Beneficence, & A Novartis Pricing Trial Balloon